Deciphering HIC1 control pathways to reveal new avenues in cancer therapeutics

Expert Opinion on Therapeutic Targets

Volumn 17, Issue 7, 2013, Pages 811-827

  Rood, Brian R ^a   Leprince, Dominique ^b  

^a CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^b INSTITUT DE BIOLOGIE DE LILLE   (France)

Author keywords

Epigenetics; HIC1; Transcriptional repression; Tumor suppressor genes

Indexed keywords

CHEMOKINE RECEPTOR CXCR7; CYCLIN D1; CYCLIN DEPENDENT KINASE 4; DOUBLE STRANDED DNA; EPHRIN A1; EPHRIN RECEPTOR A2; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 4; HISTONE DEACETYLASE 7; HISTONE METHYLTRANSFERASE; HYPERMETHYLATED IN CANCER 1; ISOPRENALINE; PEPTIDES AND PROTEINS; PROTEIN P21; PROTEIN P53; SIRTUIN 1; STROMAL CELL DERIVED FACTOR 1; TRANSCRIPTION FACTOR SOX9; UNCLASSIFIED DRUG;

BINDING AFFINITY; BINDING SITE; CANCER THERAPY; CELL CYCLE PROGRESSION; CELL MIGRATION; CELL MOTILITY; CELL PROLIFERATION; CELL SURVIVAL; CHROMOSOME 17P; CHROMOSOME ARM; DEREGULATION; DNA METHYLATION; GENE CONTROL; GENE EXPRESSION; GENE IDENTIFICATION; GENE REPRESSION; GENE SEQUENCE; GENE TARGETING; GENETIC ASSOCIATION; HUMAN; NONHUMAN; PROMOTER REGION; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; REVIEW; TRANSIENT TRANSFECTION; TUMOR SUPPRESSOR GENE;

ANIMALS; CARCINOGENESIS; EPIGENOMICS; HUMANS; KRUPPEL-LIKE TRANSCRIPTION FACTORS; NEOPLASMS; SIRTUIN 1;

EID: 84879061291     PISSN: 14728222     EISSN: 17447631     Source Type: Journal    
DOI: 10.1517/14728222.2013.788152     Document Type: Review

References (149)

1. Knudson AG Jr. Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci USA 1971; 68: 820-3
2. Makos M, Nelkin BD, Lerman MI, et al. Distinct hypermethylation patterns occur at altered chromosome loci in human lung and colon cancer. Proc Natl Acad Sci USA 1992; 89: 1929-33
3. Makos M, Nelkin BD, Chazin VR, et al. DNA hypermethylation is associated with 17p allelic loss in neural tumors. Cancer Res 1993; 53: 2715-18 (Pubitemid 23180502)
4. Makos M, Nelkin BD, Reiter RE, et al. Regional DNA hypermethylation at D17S5 precedes 17p structural changes in the progression of renal tumors. Cancer Res 1993; 53: 2719-22 (Pubitemid 23180503)
5. Fujii H, Biel MA, Zhou W, et al. Methylation of the HIC-1 candidate tumor suppressor gene in human breast cancer. Oncogene 1998; 16: 2159-64 (Pubitemid 28211691)
6. Hayashi M, Tokuchi Y, Hashimoto T, et al. Reduced HIC-1 gene expression in non-small cell lung cancer and its clinical significance. Anticancer Res 2001; 21: 535-40 (Pubitemid 32267567)
7. Crawley JJ, Furge KA. Identification of frequent cytogenetic aberrations in hepatocellular carcinoma using gene-expression microarray data. Genome Biol 2002; 3: RESEARCH0075
8. Weber-Mangal S, Sinn HP, Popp S, et al. Breast cancer in young women (< or = 35 years): genomic aberrations detected by comparative genomic hybridization. Int J Cancer 2003; 107: 583-92 (Pubitemid 37296119)
9. Cogen PH, Daneshvar L, Metzger AK, Edwards MS. Deletion mapping of the medulloblastoma locus on chromosome 17p. Genomics 1990; 8: 279-85 (Pubitemid 20335619)
10. Cogen PH, Daneshvar L, Metzger AK, et al. Involvement of multiple chromosome 17p loci in medulloblastoma tumorigenesis. Am J Hum Genet 1992; 50: 584-9
11. Saxena A, Clark WC, Robertson JT, et al. Evidence for the involvement of a potential second tumor suppressor gene on chromosome 17 distinct from p53 in malignant astrocytomas. Cancer Res 1992; 52: 6716-21
12. von Haken MS, White EC, Daneshvar-Shyesther L, et al. Molecular genetic analysis of chromosome arm 17p and chromosome arm 22q DNA sequences in sporadic pediatric ependymomas. Genes Chromosomes Cancer 1996; 17: 37-44 (Pubitemid 26327933)
13. Steichen-Gersdorf E, Baumgartner M, Kreczy A, et al. Deletion mapping on chromosome 17p in medulloblastoma. Br J Cancer 1997; 76: 1284-7 (Pubitemid 27474968)
14. Chattopadhyay P, Rathore A, Mathur M, et al. Loss of heterozygosity of a locus on 17p13.3, independent of p53, is associated with higher grades of astrocytic tumours. Oncogene 1997; 15: 871-4 (Pubitemid 27390140)
15. Aldosari N, Rasheed BK, McLendon RE, et al. Characterization of chromosome 17 abnormalities in medulloblastomas. Acta Neuropathol 2000; 99: 345-51 (Pubitemid 30179571)
16. Rood BR, Zhang H, Weitman DM, Cogen PH. Hypermethylation of HIC-1 and 17p allelic loss in medulloblastoma. Cancer Res 2002; 62: 3794-7 (Pubitemid 34728863)
17. Waha A, Koch A, Hartmann W, et al. Analysis of HIC-1 methylation and transcription in human ependymomas. Int J Cancer 2004; 110: 542-9 (Pubitemid 38658019)
18. Adesina AM, Nalbantoglu J, Cavenee WK. p53 gene mutation and mdm2 gene amplification are uncommon in medulloblastoma. Cancer Res 1994; 54: 5649-51
19. Badiali M, Iolascon A, Loda M, et al. p53 gene mutations in medulloblastoma. Immunohistochemistry, gel shift analysis, and sequencing. Diagn Mol Pathol 1993; 2: 23-8 (Pubitemid 23197494)
20. Biegel JA, Burk CD, Barr FG, Emanuel BS. Evidence for a 17p tumor related locus distinct from p53 in pediatric primitive neuroectodermal tumors. Cancer Res 1992; 52: 3391-5
21. Kool M, Korshunov A, Remke M, et al. Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, group 3, and group 4 medulloblastomas. Acta neuropathol 2012; 123: 473-84
22. Northcott PA, Jones DT, Kool M, et al. Medulloblastomics: the end of the beginning. Nat Rev Cancer 2012; 12: 818-34
23. Taylor MD, Northcott PA, Korshunov A, et al. Molecular subgroups of medulloblastoma: the current consensus. Acta Neuropathol 2012; 123: 465-72
24. McDonald JD, Daneshvar L, Willert JR, et al. Physical mapping of chromosome 17p13.3 in the region of a putative tumor suppressor gene important in medulloblastoma. Genomics 1994; 23: 229-32 (Pubitemid 24296957)
25. Hoff C, Seranski P, Mollenhauer J, et al. Physical and transcriptional mapping of the 17p13.3 region that is frequently deleted in human cancer. Genomics 2000; 70: 26-33
26. Schultz DC, Vanderveer L, Berman DB, et al. Identification of two candidate tumor suppressor genes on chromosome 17p13.3. Cancer Res 1996; 56: 1997-2002 (Pubitemid 26119896)
27. Wales MM, Biel MA, el Deiry W, et al. p53 activates expression of HIC-1, a new candidate tumour suppressor gene on 17p13.3. Nat Med 1995; 1: 570-7
28. Guerardel C, Deltour S, Pinte S, et al. Identification in the human candidate tumor suppressor gene HIC-1 of a new major alternative TATA-less promoter positively regulated by p53. J Biol Chem 2001; 276: 3078-89
29. Britschgi C, Rizzi M, Grob TJ, et al. Identification of the p53 family-responsive element in the promoter region of the tumor suppressor gene hypermethylated in cancer 1. Oncogene 2006; 25: 2030-9
30. Jenal M, Trinh E, Britschgi C, et al. The tumor suppressor gene hypermethylated in cancer 1 is transcriptionally regulated by E2F1. Mol Cancer Res 2009; 7: 916-22
31. Dehennaut V, Leprince D. Implication of HIC1 (Hypermethylated In Cancer 1) in the DNA damage response. Bull Cancer 2009; 96: E66-72
32. Jenal M, Britschgi C, Fey MF, Tschan MP. Inactivation of the hypermethylated in cancer 1 tumour suppressor-not just a question of promoter hypermethylation? Swiss Med Wkly 2010; 140: w13106
33. Issa JP, Zehnbauer BA, Kaufmann SH, et al. HIC1 hypermethylation is a late event in hematopoietic neoplasms. Cancer Res 1997; 57: 1678-81 (Pubitemid 27199658)
34. Kanai Y, Hui AM, Sun L, et al. DNA hypermethylation at the D17S5 locus and reduced HIC-1 mRNA expression are associated with hepatocarcinogenesis. Hepatology 1999; 29: 703-9 (Pubitemid 29109583)
35. Waha A, Waha A, Koch A, et al. Epigenetic silencing of the HIC-1 gene in human medulloblastomas. J Neuropathol Exp Neurol 2003; 62: 1192-201 (Pubitemid 37413829)
36. Abouzeid HE, Kassem AM, Abdel Wahab AH, et al. Promoter hypermethylation of RASSF1A, MGMT, and HIC-1 genes in benign and malignant colorectal tumors. Tumour Biol 2011; 32: 845-52
37. Yu J, Liu P, Cui X, et al. Identification of novel subregions of LOH in gastric cancer and analysis of the HIC1 and TOB1 tumor suppressor genes in these subregions. Mol Cells 2011; 32: 47-55
38. Kilinc D, Ozdemir O, Ozdemir S, et al. Alterations in promoter methylation status of tumor suppressor HIC1, SFRP2, and DAPK1 genes in prostate carcinomas. DNA Cell Biol 2012; 31: 826-32
39. Zhao G, Qin Q, Zhang J, et al. Hypermethylation of HIC1 promoter and aberrant expression of HIC1/SIRT1 might contribute to the carcinogenesis of pancreatic cancer. Ann Surg Oncol 2012; Epub ahead of print
40. Brieger J, Pongsapich W, Mann SA, et al. Demethylation treatment restores hic1 expression and impairs aggressiveness of head and neck squamous cell carcinoma. Oral Oncol 2010; 46: 678-83
41. Eguchi K, Kanai Y, Kobayashi K, Hirohashi S. DNA hypermethylation at the D17S5 locus in non-small cell lung cancers: its association with smoking history. Cancer Res 1997; 57: 4913-15 (Pubitemid 27469002)
42. Eggers H, Steffens S, Grosshennig A, et al. Prognostic and diagnostic relevance of hypermethylated in cancer 1 (HIC1) CpG island methylation in renal cell carcinoma. Int J Oncol 2012; 40: 1650-8
43. Stephen JK, Chen KM, Shah V, et al. DNA hypermethylation markers of poor outcome in laryngeal cancer. Clin Epigenetics 2010; 1: 61-9
44. Carter MG, Johns MA, Zeng X, et al. Mice deficient in the candidate tumor suppressor gene Hic1 exhibit developmental defects of structures affected in the Miller-Dieker syndrome. Hum Mol Genet 2000; 9: 413-19 (Pubitemid 30098735)
45. Chen WY, Zeng X, Carter MG, et al. Heterozygous disruption of Hic1 predisposes mice to a gender-dependent spectrum of malignant tumors. Nat Genet 2003; 33: 197-202 (Pubitemid 36177074)
46. Chen W, Cooper TK, Zahnow CA, et al. Epigenetic and genetic loss of Hic1 function accentuates the role of p53 in tumorigenesis. Cancer Cell 2004; 6: 387-98 (Pubitemid 39361439)
47. Briggs KJ, Corcoran-Schwartz IM, Zhang W, et al. Cooperation between the Hic1 and Ptch1 tumor suppressors in medulloblastoma. Genes Dev 2008; 22: 770-85 (Pubitemid 351439108)
48. Mohammad HP, Zhang W, Prevas HS, et al. Loss of a single Hic1 allele accelerates polyp formation in Apc (Delta716) mice. Oncogene 2011; 30: 2659-69
49. Bardwell VJ, Treisman R. The POZ domain: a conserved protein-protein interaction motif. Genes Dev 1994; 8: 1664-77 (Pubitemid 24236245)
50. Zollman S, Godt D, Prive GG, et al. The BTB domain, found primarily in zinc finger proteins, defines an evolutionarily conserved family that includes several developmentally regulated genes in Drosophila. Proc Natl Acad Sci USA 1994; 91: 10717-21 (Pubitemid 24329070)
51. Albagli O, Dhordain P, Deweindt C, et al. The BTB/POZ domain: a new protein-protein interaction motif common to DNA-and actin-binding proteins. Cell Growth Differ 1995; 6: 1193-8
52. Deltour S, Guerardel C, Stehelin D, Leprince D. The carboxy-terminal end of the candidate tumor suppressor gene HIC-1 is phylogenetically conserved. Biochim Biophys Acta 1998; 1443: 230-2 (Pubitemid 29016029)
53. Fleuriel C, Touka M, Boulay G, et al. HIC1 (Hypermethylated in Cancer 1) epigenetic silencing in tumors. Int J Biochem Cell Biol 2009; 41: 26-33
54. Dehennaut V, Loison I, Pinte S, Leprince D. Molecular dissection of the interaction between HIC1 and SIRT1. Biochem Biophys Res Commun 2012; 421: 384-8
55. Pinte S, Stankovic-Valentin N, Deltour S, et al. The tumor suppressor gene HIC1 (hypermethylated in cancer 1) is a sequence-specific transcriptional repressor: definition of its consensus binding sequence and analysis of its DNA binding and repressive properties. J Biol Chem 2004; 279: 38313-24 (Pubitemid 39295979)
56. Ahmad KF, Engel CK, Prive GG. Crystal structure of the BTB domain from PLZF. Proc Natl Acad Sci USA 1998; 95: 12123-8 (Pubitemid 28483729)
57. Ahmad KF, Melnick A, Lax S, et al. Mechanism of SMRT corepressor recruitment by the BCL6 BTB domain. Mol Cell 2003; 12: 1551-64 (Pubitemid 38037022)
58. Li X, Peng H, Schultz DC, et al. Structure-function studies of the BTB/POZ transcriptional repression domain from the promyelocytic leukemia zinc finger oncoprotein. Cancer Res 1999; 59: 5275-82 (Pubitemid 29503994)
59. Dhordain P, Albagli O, Ansieau S, et al. The BTB/POZ domain targets the LAZ3/BCL6 oncoprotein to nuclear dots and mediates homomerisation in vivo. Oncogene 1995; 11: 2689-97
60. Deltour S, Pinte S, Guerardel C, Leprince D. Characterization of HRG22, a human homologue of the putative tumor suppressor gene HIC1. Biochem Biophys Res Commun 2001; 287: 427-34 (Pubitemid 32917616)
61. Deltour S, Pinte S, Guerardel C, et al. The human candidate tumor suppressor gene HIC1 recruits CtBP through a degenerate GLDLSKK motif. Mol Cell Biol 2002; 22: 4890-901 (Pubitemid 34620422)
62. Valenta T, Lukas J, Doubravska L, et al. HIC1 attenuates Wnt signaling by recruitment of TCF-4 and beta-catenin to the nuclear bodies. EMBO J 2006; 25: 2326-37 (Pubitemid 44012216)
63. Li JY, English MA, Ball HJ, et al. Sequence-specific DNA binding and transcriptional regulation by the promyelocytic leukemia zinc finger protein. J Biol Chem 1997; 272: 22447-55 (Pubitemid 27386053)
64. Lours C, Bardot O, Godt D, et al. The drosophila melanogaster BTB proteins bric a brac bind DNA through a composite DNA binding domain containing a pipsqueak and an AT-hook motif. Nucleic Acids Res 2003; 31: 5389-98 (Pubitemid 37441907)
65. Barna M, Merghoub T, Costoya JA, et al. Plzf mediates transcriptional repression of HoxD gene expression through chromatin remodeling. Dev Cell 2002; 3: 499-510 (Pubitemid 35256063)
66. Chen WY, Wang DH, Yen RC, et al. Tumor suppressor HIC1 directly regulates SIRT1 to modulate p53-dependent DNA-damage responses. Cell 2005; 123: 437-48 (Pubitemid 41546674)
67. Van Rechem C, Boulay G, Pinte S, et al. Differential regulation of HIC1 target genes by CtBP and NuRD, via an acetylation/SUMOylation switch, in quiescent versus proliferating cells. Mol Cell Biol 2010; 30: 4045-59
68. Li P, Zhao Y, Wu X, et al. Interferon gamma (IFN-gamma) disrupts energy expenditure and metabolic homeostasis by suppressing SIRT1 transcription. Nucleic Acids Res 2012; 40: 1609-20
69. Briones VR, Chen S, Riegel AT, Lechleider RJ. Mechanism of fibroblast growth factor-binding protein 1 repression by TGF-beta. Biochem Biophys Res Commun 2006; 345: 595-601 (Pubitemid 43776968)
70. Tassi E, McDonnell K, Gibby KA, et al. Impact of fibroblast growth factor-binding protein-1 expression on angiogenesis and wound healing. Am J Pathol 2011; 179: 2220-32
71. Bailey SG, Cragg MS, Townsend PA. Family friction as DeltaNp73 antagonises p73 and p53. Int J Biochem Cell Biol 2011; 43: 482-6
72. Vilgelm AE, Hong SM, Washington MK, et al. Characterization of DeltaNp73 expression and regulation in gastric and esophageal tumors. Oncogene 2010; 29: 5861-8
73. el-Deiry WS, Tokino T, Velculescu VE, et al. WAF1, a potential mediator of p53 tumor suppression. Cell 1993; 75: 817-25 (Pubitemid 23346378)
74. Dehennaut V, Loison I, Boulay G, et al. Identification of p21 (CIP1/WAF1) as a direct target gene of HIC1 (Hypermethylated In Cancer 1). Biochem Biophys Res Commun 2013; 430: 49-53
75. Van Rechem C, Rood BR, Touka M, et al. Scavenger chemokine (CXC Motif) receptor 7 (CXCR7) is a direct target gene of HIC1 (Hypermethylated in Cancer 1). J Biol Chem 2009; 284: 20927-35
76. Zhang W, Zeng X, Briggs KJ, et al. A potential tumor suppressor role for Hic1 in breast cancer through transcriptional repression of ephrin-A1. Oncogene 2010; 29: 2467-76
77. Zheng J, Wang J, Sun X, et al. HIC1 modulates prostate cancer progression by epigenetic modification. Clin Cancer Res 2013; 19(6): 1400-10
78. Roussel MF, Hatten ME. Cerebellum development and medulloblastoma. Curr Top Dev Biol 2011; 94: 235-82
79. Briggs KJ, Eberhart CG, Watkins DN. Just say no to ATOH: how HIC1 methylation might predispose medulloblastoma to lineage addiction. Cancer Res 2008; 68: 8654-6
80. Ayrault O, Zhao H, Zindy F, et al. Atoh1 inhibits neuronal differentiation and collaborates with Gli1 to generate medulloblastoma- initiating cells. Cancer Res 2010; 70: 5618-27
81. Boulay G, Dubuissez M, Van Rechem C, et al. Hypermethylated in cancer 1 (HIC1) recruits polycomb repressive complex 2 (PRC2) to a subset of its target genes through interaction with human polycomb-like (hPCL) proteins. J Biol Chem 2012; 287: 10509-24
82. Singh AK, Arya RK, Trivedi AK, et al. Chemokine receptor trio: CXCR3, CXCR4 and CXCR7 crosstalk via CXCL11 and CXCL12. Cytokine Growth Factor Rev 2013; 24(1): 41-9
83. Decaillot FM, Kazmi MA, Lin Y, et al. CXCR7/CXCR4 heterodimer constitutively recruits beta-arrestin to enhance cell migration. J Biol Chem 2011; 286: 32188-97
84. Rajagopal S, Kim J, Ahn S, et al. Betaarrestin-but not G protein-mediated signaling by the decoy receptor CXCR7. Proc Natl Acad Sci USA 2010; 107: 628-32
85. Wang J, Shiozawa Y, Wang J, et al. The role of CXCR7/RDC1 as a chemokine receptor for CXCL12/SDF-1 in prostate cancer. J Biol Chem 2008; 283: 4283-94
86. Hernandez L, Magalhaes MA, Coniglio SJ, et al. Opposing roles of CXCR4 and CXCR7 in breast cancer metastasis. Breast Cancer Res 2011; 13: R128
87. Brantley-Sieders DM. Clinical relevance of Ephs and ephrins in cancer: lessons from breast, colorectal, and lung cancer profiling. Semin Cell Dev Biol 2012; 23: 102-8
88. Foveau B, Boulay G, Pinte S, et al. Receptor tyrosyne kinase Epha2 is a direct target-gene of Hic1 (Hypermethylated in Cancer 1). J Biol Chem 2012; 287: 5366-78
89. Macrae M, Neve RM, Rodriguez-Viciana P, et al. A conditional feedback loop regulates Ras activity through EphA2. Cancer Cell 2005; 8: 111-18 (Pubitemid 41132740)
90. Brantley-Sieders DM, Jiang A, Sarma K, et al. Eph/ephrin profiling in human breast cancer reveals significant associations between expression level and clinical outcome. PLoS One 2011; 6: e24426
91. Miao H, Wang B. EphA receptor signaling-complexity and emerging themes. Semin Cell Dev Biol 2012; 23: 16-25
92. Pasquale EB. Eph receptors and ephrins in cancer: bidirectional signalling and beyond. Nat Rev Cancer 2010; 10: 165-80
93. Pasquale EB. Eph-ephrin bidirectional signaling in physiology and disease. Cell 2008; 133: 38-52 (Pubitemid 351442996)
94. Boulay G, Malaquin N, Loison I, et al. Loss of hypermethylated In Cancer 1 (HIC1) in breast cancer cells contributes to stress induced migration and invasion through beta-2 adrenergic receptor (ADRB2) misregulation. J Biol Chem 2012; 287: 5379-89
95. Perez-Sayans M, Somoza-Martin JM, Barros-Angueira F, et al. Beta-adrenergic receptors in cancer: therapeutic implications. Oncol Res 2010; 19: 45-54
96. Vasanwala FH, Kusam S, Toney LM, Dent AL. Repression of AP-1 function: a mechanism for the regulation of Blimp-1 expression and B lymphocyte differentiation by the B cell lymphoma-6 protooncogene. J Immunol 2002; 169: 1922-9 (Pubitemid 34857655)
97. Deltour S, Guerardel C, Leprince D. Recruitment of SMRT/N-CoR-mSin3AHDAC- repressing complexes is not a general mechanism for BTB/POZ transcriptional repressors: the case of HIC-1 and gammaFBP-B. Proc Natl Acad Sci USA 1999; 96: 14831-6 (Pubitemid 30019725)
98. Stankovic-Valentin N, Verger A, Deltour-Balerdi S, et al. A L225A substitution in the human tumour suppressor HIC1 abolishes its interaction with the corepressor CtBP. FEBS J 2006; 273: 2879-90
99. Stankovic-Valentin N, Deltour S, Seeler J, et al. An acetylation/ deacetylation-SUMOylation switch through a phylogenetically conserved psiKXEP motif in the tumor suppressor HIC1 regulates transcriptional repression activity. Mol Cell Biol 2007; 27: 2661-75 (Pubitemid 46581356)
100. Parekh S, Polo JM, Shaknovich R, et al. BCL6 programs lymphoma cells for survival and differentiation through distinct biochemical mechanisms. Blood 2007; 110: 2067-74 (Pubitemid 47443924)
101. Bertrand S, Pinte S, Stankovic-Valentin N, et al. Identification and developmental expression of the zebrafish orthologue of the tumor suppressor gene HIC1. Biochim Biophys Acta 2004; 1678: 57-66 (Pubitemid 38456948)
102. Chinnadurai G. Transcriptional regulation by C-terminal binding proteins. Int J Biochem Cell Biol 2007; 39: 1593-607 (Pubitemid 47088308)
103. Zhang Q, Wang SY, Nottke AC, et al. Redox sensor CtBP mediates hypoxia-induced tumor cell migration. Proc Natl Acad Sci USA 2006; 103: 9029-33 (Pubitemid 43902527)
104. Zhang Q, Wang SY, Fleuriel C, et al. Metabolic regulation of SIRT1 transcription via a HIC1: ctBP corepressor complex. Proc Natl Acad Sci USA 2007; 104: 829-33 (Pubitemid 46154696)
105. Hay RT. SUMO: a history of modification. Mol Cell 2005; 18: 1-12 (Pubitemid 40444643)
106. Geiss-Friedlander R, Melchior F. Concepts in sumoylation: a decade on. Nat Rev Mol Cell Biol 2007; 8: 947-56 (Pubitemid 350176509)
107. Gareau JR, Lima CD. The SUMO pathway: emerging mechanisms that shape specificity, conjugation and recognition. Nat Rev Mol Cell Biol 2010; 11: 861-71
108. Denslow SA, Wade PA. The human Mi-2/NuRD complex and gene regulation. Oncogene 2007; 26: 5433-8 (Pubitemid 47255925)
109. Miccio A, Wang Y, Hong W, et al. NuRD mediates activating and repressive functions of GATA-1 and FOG-1 during blood development. EMBO J 2010; 29: 442-56
110. Ramirez J, Hagman J. The Mi-2/NuRD complex: a critical epigenetic regulator of hematopoietic development, differentiation and cancer. Epigenetics 2009; 4: 532-6
111. Manavathi B, Kumar R. Metastasis tumor antigens, an emerging family of multifaceted master coregulators. J Biol Chem 2007; 282: 1529-33 (Pubitemid 47076673)
112. Wang X, Nagl NG, Wilsker D, et al. Two related ARID family proteins are alternative subunits of human SWI/SNF complexes. Biochem J 2004; 383: 319-25 (Pubitemid 39446693)
113. Van Rechem C, Boulay G, Leprince D. HIC1 interacts with a specific subunit of SWI/SNF complexes, ARID1A/BAF250A. Biochem Biophys Res Commun 2009; 385: 586-90
114. Nagl NG Jr, Wang X, Patsialou A, et al. Distinct mammalian SWI/SNF chromatin remodeling complexes with opposing roles in cell-cycle control. Embo J 2007; 26: 752-63
115. Li XS, Trojer P, Matsumura T, et al. Mammalian SWI/SNF-a subunit BAF250/ARID1 is an E3 ubiquitin ligase that targets histone H2B. Mol Cell Biol 2010; 30: 1673-88
116. Bourdeaut F, Bieche I. Chromatin remodeling defects and cancer: the SWI/SNF example. Bull Cancer 2012; 99: 1133-40
117. Wang S, Robertson GP, Zhu J. A novel human homologue of Drosophila polycomblike gene is up-regulated in multiple cancers. Gene 2004; 343: 69-78 (Pubitemid 39551030)
118. Boulay G, Rosnoblet C, Guerardel C, et al. Functional characterization of human Polycomb-like 3 isoforms identifies them as components of distinct EZH2 protein complexes. Biochem J 2011; 434: 333-42
119. Morey L, Helin K. Polycomb group protein-mediated repression of transcription. Trends Biochem Sci 2010; 35: 323-32
120. Margueron R, Reinberg D. The Polycomb complex PRC2 and its mark in life. Nature 2011; 469: 343-9
121. Nekrasov M, Klymenko T, Fraterman S, et al. Pcl-PRC2 is needed to generate high levels of H3-K27 trimethylation at polycomb target genes. EMBO J 2007; 26: 4078-88 (Pubitemid 47462096)
122. Hunkapiller J, Shen Y, Diaz A, et al. Polycomb-like 3 promotes polycomb repressive complex 2 binding to CpG islands and embryonic stem cell self-renewal. PLoS Genet 2012; 8: e1002576
123. Cai L, Rothbart SB, Lu R, et al. An H3K36 methylation-engaging tudor motif of polycomb-like proteins mediates PRC2 complex targeting. Mol Cell 2013; 49: 1-12
124. Brien GL, Gambero G, O'Connell DJ, et al. Polycomb PHF19 binds H3K36me3 and recruits PRC2 and demethylase NO66 to embryonic stem cell genes during differentiation. Nat Struct Mol Biol 2012; 19: 1273-81
125. Ballare C, Lange M, Lapinaite A, et al. Phf19 links methylated Lys36 of histone H3 to regulation of polycomb activity. Nat Struct Mol Biol 2012; 19: 1257-65
126. Musselman CA, Avvakumov N, Watanabe R, et al. Molecular basis for H3K36me3 recognition by the tudor domain of PHF1. Nat Struct Mol Biol 2012; 19: 1266-72
127. Chantalat S, Depaux A, Hery P, et al. Histone H3 trimethylation at lysine 36 is associated with constitutive and facultative heterochromatin. Genome Res 2011; 21: 1426-37
128. Schmitges FW, Prusty AB, Faty M, et al. Histone methylation by PRC2 is inhibited by active chromatin marks. Mol Cell 2011; 42: 330-41
129. Vissers JH, van Lohuizen M, Citterio E. The emerging role of Polycomb repressors in the response to DNA damage. J Cell Sci 2012; 125: 3939-48
130. Hong Z, Jiang J, Lan L, et al. A polycomb group protein, PHF1, is involved in the response to DNA double-strand breaks in human cell. Nucleic Acids Res 2008; 36: 2939-47 (Pubitemid 351737186)
131. Yang Y, Wang C, Zhang P, et al. Polycomb group protein PHF1 regulates p53-dependent cell growth arrest and apoptosis. J Biol Chem 2013; 288: 529-39
132. Tseng RC, Lee CC, Hsu HS, et al. Distinct HIC1-SIRT1-p53 loop deregulation in lung squamous carcinoma and adenocarcinoma patients. Neoplasia 2009; 11: 763-70
133. Liu T, Liu PY, Marshall GM. The critical role of the class III histone deacetylase SIRT1 in cancer. Cancer Res 2009; 69: 1702-5
134. Yang XJ, Gregoire S. A recurrent phospho-sumoyl switch in transcriptional repression and beyond. Mol Cell 2006; 23: 779-86 (Pubitemid 44344522)
135. Shalizi A, Gaudilliere B, Yuan Z, et al. A calcium-regulated MEF2 sumoylation switch controls postsynaptic differentiation. Science 2006; 311: 1012-17 (Pubitemid 43271730)
136. Hietakangas V, Anckar J, Blomster HA, et al. PDSM, a motif for phosphorylation-dependent SUMO modification. Proc Natl Acad Sci USA 2006; 103: 45-50 (Pubitemid 43076102)
137. Gregoire S, Yang XJ. Association with class IIa histone deacetylases upregulates the sumoylation of MEF2 transcription factors. Mol Cell Biol 2005; 25: 2273-87 (Pubitemid 40354624)
138. Zhao X, Sternsdorf T, Bolger TA, et al. Regulation of MEF2 by histone deacetylase 4-and SIRT1 deacetylase-mediated lysine modifications. Mol Cell Biol 2005; 25: 8456-64 (Pubitemid 41369167)
139. Gao C, Ho CC, Reineke E, et al. Histone deacetylase 7 promotes PML sumoylation and is essential for PML nuclear body formation. Mol Cell Biol 2008; 28: 5658-67
140. Dehennaut V, Loison I, Dubuissez M, et al. DNA double-strand breaks lead to activation of Hyperrmethylated in Cancer 1 (HIC1) gene by SUMOylation to regulate DNA repair. J Biol Chem 2013; Epub ahead of print
141. Kang H, Suh JY, Jung YS, et al. Peptide switch is essential for Sirt1 deacetylase activity. Mol Cell 2011; 44: 203-13
142. Kang H, Jung JW, Kim MK, Chung JH. CK2 is the regulator of SIRT1 substrate-binding affinity, deacetylase activity and cellular response to DNA-damage. PLoS ONE 2009; 4: e6611
143. Nebbioso A, Carafa V, Benedetti R, Altucci L. Trials with 'epigenetic' drugs: an update. Mol Oncol 2012; 6: 657-82
144. Amatori S, Bagaloni I, Donati B, et al. A demethylating antineoplastic strategies: a comparative point of view. Genes Cancer 2010; 1: 197-209
145. Veeck J, Esteller M. Breast cancer epigenetics: from DNA methylation to microRNAs. J Mammary Gland Biol Neoplasia 2010; 15: 5-17
146. Yap DB, Chu J, Berg T, et al. Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation. Blood 2011; 117: 2451-9
147. Knutson SK, Wigle TJ, Warholic NM, et al. A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells. Nat Chem Biol 2012; 8: 890-6
148. Melnick A. Epigenetic therapy leaps ahead with specific targeting of EZH2. Cancer Cell 2012; 22: 569-70
149. McCabe MT, Ott HM, Ganji G, et al. EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature 2012; 492: 108-12